Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion type Assertion NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_head.
- NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_provenance.
- NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion evidence source_evidence_literature NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_provenance.
- NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion SIO_000772 23769318 NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_provenance.
- NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion wasDerivedFrom befree-20150227 NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_provenance.
- NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion wasGeneratedBy ECO_0000203 NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_provenance.